A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Summary
Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete understanding of potentially druggable immune mediators of disease. To advance this, we present a comprehensive multi-omic blood atlas in patients with varying COVID-19 severity and compare with influenza, sepsis and healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity revealed cells, their inflammatory mediators and networks as potential therapeutic targets, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Tensor and matrix decomposition of the overall dataset revealed feature groupings linked with disease severity and specificity. Our systems-based integrative approach and blood atlas will inform future drug development, clinical trial design and personalised medicine approaches for COVID-19.
Competing Interest Statement
RBR is a cofounder and consultant of Alchemab Therapeutics Ltd. RC is Founder of MIROBio. JH is Director and shareholder of Nucleome Therapeutics. GS sits on GSK Vaccines SAB.
Funding Statement
The research was supported by the University of Oxford COVID-19 Research Response Fund, Wellcome Trust Core Award Grant Number 203141/Z/16/Z and the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
South Central Oxford C Research Ethics Committee (REC) in England (Sepsis Immunomics REC reference 19/SC/0296; ISARIC WHO Clinical Characterisation Protocol for Severe Emerging Infections REC reference 13/SC/0149)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data from our study can be explored interactively through a web portal: https://mlv.combat.ox.ac.uk/
Subject Area
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2600)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12139)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4035)
- Geriatric Medicine (380)
- Health Economics (671)
- Health Informatics (2607)
- Health Policy (995)
- Hematology (359)
- HIV/AIDS (833)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3804)
- Nursing (208)
- Nutrition (567)
- Oncology (1991)
- Ophthalmology (578)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (250)
- Palliative Medicine (73)
- Pathology (470)
- Pediatrics (1100)
- Primary Care Research (443)
- Public and Global Health (6473)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (51)
- Transplantation (185)
- Urology (165)